A Randomized Controlled Phase II Clinical Trial With Intradermal IMO-2125 (Tilsotolimod) in pT3-4 cN0M0 Melanoma
Latest Information Update: 09 Feb 2023
At a glance
- Drugs Tilsotolimod (Primary)
- Indications Malignant melanoma
- Focus Therapeutic Use
- Acronyms Intrim 1 Study
- 17 Jan 2023 According to an Aceragen media release, Idera Pharmaceuticals has changed its name to Aceragen.
- 13 Sep 2022 Primary endpoint has been met (The rate of tumor positive sentinel lymph nodes (SLN)) , according to Results presented at the 47th European Society for Medical Oncology Congress
- 13 Sep 2022 Interim efficacy and safety results (n=108) presented at the 47th European Society for Medical Oncology Congress